• In the second quarter of 2026, Colgate-Palmolive reported higher sales of US$5,361 million but lower net income of US$693 million compared with a year earlier, while first-half results showed a similar pattern of sales growth and reduced earnings.
• Despite this mix of rising revenue and softer profitability, the company maintained its full-year 2026 outlook for net sales growth of 2% to 6% and double-digit GAAP earnings per share growth, signaling confidence in its underlying plan.
• Next, we’ll examine how reaffirming full-year earnings guidance despite softer quarterly profitability influences Colgate-Palmolive’s existing investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Colgate-Palmolive Investment Narrative Recap

To own Colgate-Palmolive, you need to believe its global brands can convert steady household demand into consistent cash generation, even when margins tighten. The latest quarter showed higher sales but lower earnings, so it does not materially change the near term focus on margin pressure as a key risk or on management’s ability to deliver the reaffirmed 2026 earnings targets as a short term catalyst.

The most relevant recent announcement here is Colgate-Palmolive’s decision on 31 July 2026 to maintain its full year outlook for 2% to 6% net sales growth and double digit GAAP EPS growth. That guidance sits alongside softer first half profitability and keeps attention squarely on whether the company can offset cost inflation and competitive pressures while still lifting earnings over the rest of the year.

But investors should still be aware of the risk that rising raw material and packaging costs could...

Colgate-Palmolive's narrative projects $23.1 billion revenue and $3.4 billion earnings by 2029. This requires 3.2% yearly revenue growth and about a $1.4 billion earnings increase from $2.0 billion today.

Uncover how Colgate-Palmolive's forecasts yield a $98.95 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value Colgate-Palmolive between US$98.95 and about US$130.82 per share, showing a wide span of expectations. You can weigh those views against the current concern that higher input costs may continue to pressure margins and influence how reliably the company can translate sales into earnings.

Explore 3 other fair value estimates on Colgate-Palmolive - why the stock might be worth just $98.95!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Colgate-Palmolive research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.